Cargando…

A Real-World Study in Advanced Non–Small Cell Lung Cancer with KRAS Mutations

BACKGROUND: KRAS gene mutations are well known as a key driver of advanced non–small cell lung cancer (NSCLC). The impact of KRAS-mutant subtypes on the survival benefit from salvage chemotherapy is controversial. Here, we present a real-world study in patients across China with advanced NSCLC with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lei, Lei, Wang, Wen-xian, Yu, Zong-yang, Liang, Xian-bin, Pan, Wei-wei, Chen, Hua-fei, Wang, Li-ping, Fang, Yong, Wang, Min, Xu, Chun-wei, Fang, Mei-yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2019
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031095/ https://www.ncbi.nlm.nih.gov/pubmed/31881505 http://dx.doi.org/10.1016/j.tranon.2019.12.004

Ejemplares similares

Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study
por: Lei, Lei, et al.
Publicado: (2019)

A real-world study in advanced non-small cell lung cancer with de novo brain metastasis
por: Lei, Lei, et al.
Publicado: (2021)

Association between BRAF mutant classification and the efficacy of pemetrexed-based chemotherapy in Chinese advanced non-small cell lung cancer patients: a multicenter retrospective study
por: Lei, Lei, et al.
Publicado: (2020)

Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib
por: Zhu, You-Cai, et al.
Publicado: (2019)

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
por: Wang, Lei, et al.
Publicado: (2014)

KRAS mutated Non‐Small Lung Carcinoma: A Real World Context from the Indian subcontinent
por: Batra, Ullas, et al.
Publicado: (2022)

Potential mechanism of primary resistance to icotinib in patients with advanced non–small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi‐center study
por: Lei, Lei, et al.
Publicado: (2020)

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review
por: Zhu, You‐cai, et al.
Publicado: (2017)

The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study
por: Yu, Xiaoqing, et al.
Publicado: (2022)

Identification of KRAS mutation in a patient with linear nevus sebaceous syndrome: a case report
por: Pan, Chun, et al.
Publicado: (2020)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non‐squamous non‐small cell lung cancer patients
por: Liu, Feiwen, et al.
Publicado: (2023)

The Diverse Analysis Identifies Mutated KRAS Associated With Radioresistance in Non-Small Cell Lung Cancer
por: Zhu, Dao Qi, et al.
Publicado: (2022)

A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
por: Liu, Yanxia, et al.
Publicado: (2022)

The prevalence and real‐world therapeutic analysis of Chinese patients with KRAS‐Mutant Non‐Small Cell lung cancer
por: Chen, Hanxiao, et al.
Publicado: (2022)

Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
por: Noordhof, Anneloes L., et al.
Publicado: (2023)

Effect of icotinib on advanced lung adenocarcinoma patients with sensitive EGFR mutation detected in ctDNA by ddPCR
por: Chen, Hua-Fei, et al.
Publicado: (2019)

Treatment and prognosis of primary malignant melanoma of the esophagus
por: Cheng, Lei, et al.
Publicado: (2020)

Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study
por: Xu, Chun-Wei, et al.
Publicado: (2020)

The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer
por: Liu, Lei, et al.
Publicado: (2023)

Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study
por: Illini, Oliver, et al.
Publicado: (2022)

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer
por: Fakih, Marwan, et al.
Publicado: (2022)

KRAS mutation: from undruggable to druggable in cancer
por: Huang, Lamei, et al.
Publicado: (2021)

Real-world Evidence of the Herb-drug Interactions
por: Pan, Hsueh-Yi, et al.
Publicado: (2022)

Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting
por: Julian, Cristina, et al.
Publicado: (2023)

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
por: Zeng, Da-xiong, et al.
Publicado: (2017)

TP53 Mutation Mapping in Advanced Non-Small Cell Lung Cancer: A Real-World Retrospective Cohort Study
por: Hao, Fang, et al.
Publicado: (2022)

Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report
por: Fang, Cheng, et al.
Publicado: (2019)

Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data
por: Guo, Gui-Fang, et al.
Publicado: (2019)

Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non–Small Cell Lung Cancer and Response to EGFR TKIs
por: Xu, Chun-wei, et al.
Publicado: (2020)

Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screening
por: Yang, Yang, et al.
Publicado: (2016)

Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex EGFR mutations: a real-world study
por: Li, Hong-Shuai, et al.
Publicado: (2022)

Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
por: Sun, Jong-Mu, et al.
Publicado: (2013)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
por: Liu, Yu-Huei, et al.
Publicado: (2022)

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
por: Sun, Haiyan, et al.
Publicado: (2023)

Prognostic value of KRAS mutation status in colorectal cancer patients: a population-based competing risk analysis
por: Dai, Dongjun, et al.
Publicado: (2020)

Complete response to sotorasib as neoadjuvant treatment in patient with locally advanced primary pulmonary sarcoma harboring KRAS mutation: a case report
por: Li, Ce, et al.
Publicado: (2022)

The Advance and Correlation of KRAS Mutation With the Fertility-Preservation Treatment of Endometrial Cancer in the Background of Molecular Classification Application
por: Yu, KeXuan, et al.
Publicado: (2021)

Real-world treatment patterns and survival for locally advanced esophageal squamous cell carcinoma
por: Luo, Hua-Chun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q85v49cl36sm4d05rhndv1b7h0